Fox Chase Cancer Center News

PHILADELPHIA (September 15, 2022)—The Supportive Oncology and Palliative Care Program (SOPCP) at Fox Chase Cancer Center has earned Joint Commission Advanced Palliative Care Certification, marking the fourth consecutive time the program has achieved this distinction.

PHILADELPHIA (September 14, 2022)—Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology (ASCB), making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.

PHILADELPHIA (September 13, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Anthony M. Villano, MD, as a clinical instructor in the Department of Surgical Oncology.

PHILADELPHIA (September 12, 2022)—Camille Ragin, PhD, MPH will serve as co-chair and participate in a panel discussion at this year’s 15th Annual American Association for Cancer Research (AACR) Conference.

PHILADELPHIA (September 12, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Hayan Lee, PhD, as an assistant professor in the Cancer Signaling and Epigenetics research program and the Cancer Epigenetics Institute (CEI).

PHILADELPHIA (September 2 2022)—In a recent study, researchers at Fox Chase Cancer Center demonstrated how cancer cells can survive in the body even when faced with a lack of sufficient nutrition, a finding that could be used as a potential indicator of disease status in the organs of pancreatic cancer patients.

PHILADELPHIA (August 31, 2022)—Researchers at Fox Chase Cancer Center co-authored a multi-institutional study that found that an RNA modification enzyme is critical for the survival of motor neurons. The scientists say the findings could help in the development of new treatments for neurological and other aging-related disorders, including cancer.

PHILADELPHIA (August 30, 2022)—Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.